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Background The onset of Leber hereditary optic
neuropathy (LHON) is relatively rare in childhood. This
study describes the clinical and molecular genetic
features observed in this specific LHON subgroup.
Methods Our retrospective study consisted of a UK
paediatric LHON cohort of 27 patients and 69 additional
cases identified from a systematic review of the
literature. Patients were included if visual loss occurred
at the age of 12 years or younger with a confirmed
pathogenic mitochondrial DNA mutation: m.3460G>A,
m.11778G>A or m.14484T>C.
Results In the UK paediatric LHON cohort, three
patterns of visual loss and progression were observed:
(1) classical acute (17/27, 63%); (2) slowly progressive
(4/27, 15%); and (3) insidious or subclinical (6/27,
22%). Diagnostic delays of 3–15 years occurred in
children with an insidious mode of onset. Spontaneous
visual recovery was more common in patients carrying
the m.3460G>A and m.14484T>C mutations compared
with the m.11778G>A mutation. Based a meta-analysis
of 67 patients with available visual acuity data, 26
(39%) patients achieved a final best-corrected visual
acuity (BCVA) ≥0.5 Snellen decimal in at least one eye,
whereas 13 (19%) patients had a final BCVA <0.05 in
their better seeing eye.
Conclusions Although childhood-onset LHON carries a
relatively better visual prognosis, approximately 1 in 5
patients will remain within the visual acuity criteria for
legal blindness in the UK. The clinical presentation can
be insidious and LHON should be considered in the
differential diagnosis when faced with a child with
unexplained subnormal vision and optic disc pallor.
INTRODUCTION
Leber hereditary optic neuropathy (LHON) (OMIM
535000) is a mitochondrial disorder that classically
presents with acute or subacute bilateral loss of
central vision in young adult men.1–3 About 90% of
patients carry one of the three major disease-causing
LHON mitochondrial DNA (mtDNA) mutations
(MTND1m.3460G>A, MTND4m.11778G>A and
MTND6m.14484T>C), all of which encode for crit-
ical complex I subunits of the mitochondrial respira-
tory chain.4 The greater availability of molecular
genetic testing has broadened the phenotypical spec-
trum associated with LHON to include patients with
more slowly progressive visual deterioration exceed-
ing 6 months in duration, and those with an insidi-
ous/subclinical course characterised by the incidental
discovery of subnormal vision and optic atrophy in
the absence of overt visual symptoms.1 5 Although
disease conversion can occur anywhere from the first
to the eight decade of life, the peak age of onset of
visual loss among LHON carriers is 20–30 years
old.1 4 Childhood-onset disease is relatively rare and
less than 10% of patients were 12 years old or
younger at the time of diagnosis in previously pub-
lished case series.1 6–10 Although there are limited
data on this important patient subgroup, the pheno-
type seems distinct from classical adult-onset LHON
with atypical patterns of vision loss and a better
visual prognosis as reported in a previously published
study of 18 patients with childhood-onset LHON.7
The aim of our study was to describe the clinical
and molecular genetic characteristics associated
with childhood-onset LHON, in particular the
disease course and visual prognosis to better
inform genetic counselling. We retrieved data for
all eligible patients with LHON that were seen at
three major diagnostic centres for inherited optic
neuropathies in the UK. This UK paediatric LHON
cohort was then combined with additional cases
identified from a systematic review of the literature




This is a retrospective observational study approved
by the local ethics committee at Moorfields Eye
Hospital and it conformed to the standards set by
the Declaration of Helsinki. Patients with LHON
with disease onset at the age of 12 years or younger
were identified from the clinical and genetic data-
bases of the three main national diagnostic centres
for inherited optic neuropathies in the UK (London,
Oxford and Newcastle upon Tyne). We only
included patients who carried one of the three
canonical pathogenic mtDNA mutations, that is,
m.3460G>A, m.11778G>A and m.14484T>C.
Additional clinical information where relevant was
sought from the original referring clinicians.
Best-corrected visual acuities (BCVAs) at disease
onset, at the nadir and at the last follow-up clinic
visit were recorded. Patients were subclassified into
three groups based on the mode of onset and pro-
gression of vision loss: (1) acute, if visual acuity
deteriorated rapidly reaching the nadir within
6 months from disease onset; (2) slowly progressive,
if visual deterioration occurred over a period
exceeding 6 months; and (3) insidious or subclin-
ical, if the patient was clinically asymptomatic at the
time that a diagnosis of optic atrophy or subnormal
vision was made, and there was no change in visual
acuity during subsequent follow-ups.1 7 Spontan-
eous visual recovery was defined as an improvement
of BCVA by two lines or more on the ETDRS chart
or from off-chart to on-chart visual acuity (0.05
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Snellen decimal (SD)). A binocular visual acuity of at least 0.5 (6/
12) is the minimum standard for driving in the UK (https://www.
gov.uk/driving-eyesight-rules, accessed on 8 November 2016)
and below 0.05 (3/60) is the legal definition of registrable blind-
ness in the UK (https://www.gov.uk/government/publications/
guidance-published-on-registering-a-vision-impairment-as-a-
disability, accessed on 8 November 2016).
When available, spectral-domain optical coherence tomog-
raphy (SD-OCT) data were retrieved from the database of the
Spectralis (Heidelberg Engineering, Heidelberg, Germany) and
Cirrus HD-OCT 4000 (Carl Zeiss Meditec, Dublin, California,
USA) platforms, and compared with the normative data
described elsewhere.11 12
Systematic literature review
A comprehensive literature search was conducted using the search
terms ‘LHON’, ‘Leber hereditary optic neuropathy’or ‘Leber’s
hereditary optic neuropathy’ and ‘child’, ‘childhood’, ‘paediatric’
or ‘paediatric’ on PubMed (https://www.ncbi.nlm.nih.gov/
pubmed/, accessed on 8 November 2016). We also reviewed all
the papers that included previously published publications on
childhood LHON in their reference lists. A patient with LHON
was included in our meta-analysis only if there was confirmation
of the m.3460G>A, m.11778G>A or m.14484T>C mtDNA
mutation, and disease onset was clearly stated as being before the
age of 12 years or younger. None of the patients included in the
historical case series was present in the UK paediatric LHON
cohort. Due to the retrospective nature of our systematic literature
review, more detailed clinical information regarding visual acuity
and disease progression was not available for 29 of the 69 eligible
patients included in our historical case series.
Statistical analysis
The Kruskal-Wallis test and Mann-Whitney U independent
samples test were used for comparing the age at onset between
the LHON genotypes and the distribution of retinal layer thick-
ness in LHON and control eyes, respectively. The Spearman’s
rank correlation test was used to assess for the strength of
dependence between BCVA and retinal layer thickness (IBM
Statistical Package of Social Sciences (SPSS) 22 V.100).
RESULTS
UK paediatric LHON cohort
The UK paediatric LHON cohort included 27 patients who were
2–11 years old (mean=6.9 years, SD=2.9 years) at the time of
onset of visual loss or when subnormal visual acuity or optic disc
pallor first became apparent (table 1). Thirteen patients (48%)
carried the m.11778G>A mutation, seven patients (26%) the
m.3460G>A mutation and seven patients (26%) the
m.14484T>C mutation (table 2). Patients 24–27 belonged to the
same family and out of five affected family members, four of them
developed visual loss before the age of 6 years. There was a known
family history of LHON in 19 probands (70%). The male:female
ratio varied between 2.5 and 3.3 for the three primary LHON
mtDNA mutations with an overall male:female ratio of 3.0. There
was no statistically significant difference in the age of disease onset
between the LHON genotypes (Kruskal-Wallis test, p=0.831).
The majority of patients (17/27, 63%) experienced acute or
subacute visual loss with the nadir being reached within
6 months of first disease onset. This mode of presentation was
the most common in children harbouring the m.3460G>A
mutation (6/7, 86%). In four patients (15%), visual acuity dete-
riorated slowly over a period extending up to 2 years. Three
patients in this subgroup carried the m.14484T>C mutation
and one the m.11778G>A mutation. There was an unexpect-
edly large number of children (6/27, 22%) with insidious or
subclinical vision loss in the UK paediatric LHON cohort.
Subnormal vision or optic disc pallor were detected during the
first 2 years of life (n=4) or after failing the preschool visual
screening assessment (n=2), which is mandatory in the UK for
all 4–5-year-olds (table 1). None of these children demonstrated
or were suspected of having impaired visual performance during
their early years and no visual deterioration occurred on subse-
quent follow-up. Molecular genetic confirmation of LHON in
this insidious/subclinical group was markedly delayed between 3
years and 15 years due to the atypical presentation.
The mean final BCVA in the whole group of patients with
childhood-onset LHON was 0.39 SD (SD=0.38, range=light
perception—1.2 SD, median=0.25) with a mean disease dur-
ation of 18 years (SD=16 years, range=1–56 years, median=16
years). BCVA was ≥0.5 in 20/54 (37%) eyes and 14/27 (52%)
patients had at least 1 eye with BCVA ≥0.5. Conversely, BCVA
was <0.05 in 11/54 (20%) eyes and 5/27 (19%) patients met
the legal definition of blindness with a BCVA<0.05 in their
better seeing eye. The m.11778G>A mutation was associated
with a worse visual outcome compared with the m.3460G>A
and m.14484T>C mutations (table 2 and figure 1). Ten (37%)
patients had asymmetrical final BCVA with a difference ≥2 lines
on the ETDRS chart, and this was associated with: (1) asymmet-
rical visual loss in the acute stage (n=2); (2) asymmetrical visual
recovery following an acute disease onset (n=2); (3) slowly pro-
gressive visual loss (n=3); and (4) an insidious/subclinical course
(n=3). Patient 26, who harboured the m.14484T>C mutation,
presented with slowly progressive visual deterioration in only
one eye. In patients presenting with acute LHON, spontaneous
visual recovery occurred in 20/34 (59%) eyes and 16 (80%) of
the recovered eyes achieved a BCVA ≥0.5. The mean time to
recovery was 29 months (SD=18 months, range=9–60 months)
and there were no significant differences between mutation sub-
groups (m.3460G>A, mean=28 months; m.11778G>A,
mean=27 months; m.14484T>C, mean=32 months; Kruskal-
Wallis test, p=0.958). Visual outcome was bimodal in the acute
LHON group with a BCVA ≥0.5 in 17/34 (50%) eyes and
<0.05 in 10/34 (29%) eyes (figure 2). The majority of eyes for
patients classified as having slowly progressive (5/8, 63%) or
insidious/subclinical (11/12, 82%) LHON had BCVA <0.5.
SD-OCT imaging of the optic nerve head was available for 26
eyes of 13 patients. There was a significant reduction in the
average peripapillary retinal nerve fibre layer (RNFL) thickness
ranging from 49.0% to 58.4% compared with control values. On
subgroup analysis, there was no significant correlation between
BCVA and peripapillary RNFL thickness in any of the individual
quadrants (data not shown). Perifoveal volumetric retinal SD-
OCT scans were available for 10 eyes of five patients. Retinal
thickness was significantly reduced in the LHON group (mean
±SD=295.5±17.7 μm) compared with normal controls (mean
±SD=340.8±13.3 μm, Mann-Whitney U test, p<0.001). This
was specifically due to marked thinning of the ganglion cell layer-
inner plexiform layer (GCL-IPL) complex in the LHON group
(mean±SD=43.2±2.9 μm) compared with normal controls
(mean±SD=93.5±7.8 μm, Mann-Whitney U test, p<0.001).
There was a statistically significant correlation between BCVA
and the remaining GCL-IPL thickness (Spearman’s r=−0.773,
p=0.009, online supplementary figure S1).
Meta-analysis of childhood-onset LHON
Our systematic review of the literature identified 69 patients
with LHON with onset of vision loss at the age of 12 years or
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younger (mean=8.5 years, median=8.0 years, range=3–12
years) from 20 original publications covering diverse popula-
tions: Australia, Brazil, Chile, China, Finland, France, Germany,
Italy, Saudi Arabia, Switzerland, the UK and USA (see online
supplementary table S1 and online supplementary appendix).
The m.11778G>A mutation accounted for 47/69 (69%) of all
the included cases. Visual acuity data were available for 40
patients and overall, 18/79 (23%) eyes achieved a BCVA ≥0.5
whereas 18/79 (23%) eyes achieved a BCVA <0.05. We merged
the UK paediatric and historical LHON cohorts to generate a
meta-analysis of childhood-onset LHON (see online
supplementary table S2 and figure S2). The number of patients








onset Disease progression RE LE
Time from
onset (years)
1 11778 Yes f 6 S Gradual visual deterioration over 2 years. 0.17 0.02 47
2 11778 Yes f 8 A No recovery. LP LP 56
3 11778 Yes f 9 A No recovery. 0.03 0.03 38
4 11778 Yes m 11 A Worst BCVA: HM BE. Recovery within 12 months from onset. 0.76 0.50 1
5 11778 No m 8 A No recovery. CF CF 33
6 11778 No m 3 I Subnormal vision since birth. 0.17 0.50 52
7 11778 No m 9 A Worst BCVA: 0.08 RE, 0.4 LE. Asymmetrical. 0.10 0.50 18
8 11778 Yes m 11 A No recovery. 0.07 0.10 2
9 11778 No m 2 I Subnormal vision detected when 2 years old. LHON diagnosed
at the age of 8 years.
0.25 0.08 17
10 11778 Yes m 8 A No recovery. CF CF 10
11 11778 No m 10 A Worst BCVA: CF BE. Recovery within 24 months from onset.
Asymmetrical recovery.
0.08 0.66 7
12 11778 Yes m 2 I Subnormal vision detected when 2 years old. LHON diagnosed
at the age of 6 years with BCVA of 0.18 RE and 0.17 LE. Slow
visual recovery until 10 years old.
0.35 0.36 4
13 11778 Yes m 2 I Optic atrophy noted at the age of 2 years. LHON diagnosed at
the age of 17 years.
0.40 0.10 15
14 3460 Yes f 7 A Worst BCVA: 0.05 BE. Recovery within 4 years from onset. 0.79 0.79 4.5
15 3460 No f 11 A No recovery. CF CF 10
16 3460 Yes m 4 I Poor visual acuity noticed at preschool screening assessment. 0.17 0.17 16
17 3460 No m 6 A Asymmetrical visual recovery. 0.67 0.25 18
18 3460 Yes m 8 A Worst BCVA: 0.05 BE. Recovery within 12 months from onset. 1.20 1.20 1
19 3460 Yes m 10 A Worst BCVA: HM RE, CF LE. Recovery. 0.33 0.50 1.5
20 3460 No m 5 A Worst BCVA: 0.1 BE. Recovery within 24 months from onset. 1.00 1.00 2
21 14484 Yes f 9 S Gradual visual deterioration over 2 years. 0.17 0.25 29
22 14484 Yes m 10 A Recovery within 9 months from onset. 1.00 1.00 16
23 14484 Yes m 5 I Poor visual acuity noticed at preschool screening assessment. 0.25 0.25 39
24† 14484 Yes f 6 A Worst BCVA: 0.02 RE, 0.2 LE. Recovery within 5 years from
onset.
0.91 1.00 18
25† 14484 Yes m 6 S Asymmetrical visual recovery. 0.69 0.14 13
26† 14484 Yes m 4 S Slowly progressive visual deterioration in the LE only. 1.00 0.10 13
27† 14484 Yes m 5 A Off-chart vision (BE) at the nadir. Asymmetrical recovery
within 2–3 years from onset.
0.07 0.67 28
*BCVA recorded at last follow-up clinic visit in Snellen decimal.
†From the same pedigree.
A, acute; BCVA, best corrected visual acuity; BE, both eyes; CF, counting fingers at 0.25 metre; f, female; HM, hand movement; I, insidious; LE, left eye; LP, light perception; m, male;
RE, right eye; S, slowly progressive.














recovery* BCVA BCVA†≥0.5 BCVA†<0.05
Mutation n f m m:f Mean, Median n (%) n (%) n (%) n (%) Mean, Median n (%) n (%)
11778 13 (13) 3 10 3.3 6.8, 8.0 8 (61) 1 (7) 4 (30) 6 (23) 0.20, 0.10 5/26 (19) 9/26 (35)
3460 7 (7) 2 5 2.5 7.3, 7.0 6 (86) 0 1 (14) 8 (57) 0.60, 0.73 8/14 (57) 2/14 (14)
14484 7 (4) 2 5 2.5 6.4, 6.0 3 (29) 3 (29) 1 (14) 6 (43) 0.54, 0.46 7/14 (50) 0/14 (0)
All 27 (24) 7 21 3.0 6.9, 7.0 17/27 (63) 4/27 (15) 6/27 (22) 20/54 (37) 0.39, 0.25 20/54 (37) 11/54 (20)
*Number of eyes with visual recovery.
†Number of eyes with BCVA ≥0.5 or <0.05 in Snellen decimal.
BCVA, best corrected visual acuity; f, female; LHON, Leber hereditary optic neuropathy; m, male.
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with a BCVA ≥0.5 in at least one eye was 26/67 (39%) whereas
the number of patients with a BCVA <0.05 in their better
seeing eye was 13/67 (19%).
DISCUSSION
LHON is a disease of young adults and due to its relative rarity,
there are limited data on the clinical features and visual progno-
sis of childhood LHON. In this study, we first identified a UK
paediatric LHON cohort consisting of 27 patients diagnosed
before the age of 12 years, which was then combined with a his-
torical cohort of 69 eligible patients from 20 previously pub-
lished reports (see online supplementary appendix). These two
cohorts had similar clinical and molecular genetic profiles and
we therefore combined the data to generate a meta-analysis for
a more comprehensive comparison with classical adult-onset
LHON.
The distribution of the three major disease-causing LHON
mutations (m.3460G>A=19%, m.11778G>A=62.5% and
m.14484T>C=19%) in the childhood cohort is comparable
with previously reported adult LHON case series with the
m.11778G>A mtDNA mutation being the most common geno-
type. As expected, there was a male preponderance, but the
overall male:female ratio of 1.8 is less marked than the fourfold
to fivefold increased risk of visual loss seen among adult male
carriers.13 14 The mechanisms contributing to this rather intri-
guing male bias are not fully understood and a number of sec-
ondary genetic, hormonal and environmental risk factors have
been implicated.15 Smoking and to a lesser extent heavy drink-
ing are regarded as important environmental triggers, but these
factors are unlikely to be aetiologically important in young chil-
dren. Although this hypothesis needs to be formally verified, the
less pronounced sex bias in childhood LHON could arise
because it is more heavily genetically determined by nuclear
modifiers, which contribute to an earlier age of onset, but that
are less sex determined or influenced. The other phenotypical
extreme would be late-onset adult cases over the age of 50 years
where environmental risk factors, in particular smoking, are
thought to play a more prominent role in precipitating disease
conversion.16 17 A systematic genomic comparison of childhood
LHON, classical acute cases in young adults and late-onset
LHON could therefore prove the key to dissecting the complex
genetic-environmental modulators that contribute to visual loss
in different groups of susceptible carriers.
The classical acute pattern of vision loss was the most
common presentation in childhood LHON, but over a third of
patients either had a slowly progressive onset or even more
strikingly, a subclinical or insidious disease evolution. In a previ-
ous report of 14 children with LHON from Barboni and collea-
gues, the 6 patients classified as having a slowly progressive
course achieved better final visual acuities compared with the
acute group.7 In contrast with this finding, the four patients in
the UK paediatric LHON cohort did not have a better progno-
sis, with the vision deteriorating in the majority of eyes to less
than the driving standards, that is, BCVA <0.5. The insidious/
subclinical LHON subgroup was observed with all three major
disease-causing mtDNA mutations and the defining observation
was the significant delays in reaching a confirmed molecular
diagnosis, which ranged from 3 years to 15 years. Visually
asymptomatic children in whom subnormal vision and optic
atrophy, which can be subtle, are detected incidentally have
been reported previously and the diagnostic challenges are likely
to be multifactorial.10 18 Visual performance in this age group is
not always impaired due to the inherent adaptive capacity of
young children and importantly, they may not be able to com-
municate changes in their vision effectively to their parents or
guardians. A lack of clinical awareness of LHON in young chil-
dren is also likely to be relevant in explaining the diagnostic
delays in this patient group.
LHON has a major impact on quality of life and the majority
of patients will remain within the criteria for legal blindness.19
The observed overall rates of spontaneous visual recovery of
37% for all eyes in the entire UK paediatric LHON cohort and
of 59% for the eyes of patients with acute LHON, are in line
with the corresponding values of 28% and 63% reported by
Barboni and colleagues.7 Patients with adult-onset LHON har-
bouring the m.14484T>C mutation have the best visual prog-
nosis with a partial visual recovery rate of 37%–58% compared
with 4%–25% for the m.11778G>A mutation and 22%–25%
for the m.3460G>A mutation.6 8 20–22 The variations in the
reported rates of spontaneous visual recovery reflect possible
sampling bias depending on the cohort size and the different
criteria used to define a visually significant change in visual
acuity from the nadir.3 In our study, the rates of spontaneous
visual recovery were 57%, 23% and 43% for the m.3460G>A,
m.11778G>A and m.14484T>C mutations, respectively.
Children carrying the m.3460G>A mutation therefore seem to
have a better visual prognosis, and the recovery rate observed
Figure 1 Distribution of best-corrected visual acuity (BCVA) in the UK
paediatric Leber hereditary optic neuropathy (LHON) cohort stratified
according to the genotype. Off-chart refers to the number of eyes with
BCVA worse than 0.05.
Figure 2 Distribution of best-corrected visual acuity (BCVA) in the UK
paediatric Leber hereditary optic neuropathy (LHON) cohort stratified
according to the pattern of visual loss at disease onset. Off-chart refers
to the number of eyes with BCVA worse than 0.05.
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with the m.11778G>A mutation is also higher, compared with
the clinical impression in patients with adult-onset LHON.6 21
Based on our meta-analysis of 67 patients for whom visual
acuity data were available, 39% of patients achieved a BCVA
≥0.5 in at least one eye whereas 19% of patients had a BCVA
<0.05 in their better seeing eye. A more favourable final visual
outcome was observed for all three genotypes in our childhood-
onset LHON cohort compared with previously published
figures (m.3460G>A: 14% vs 55%–96%; m.11778G>A: 45%
vs 73%–98%; and m.14484T>C mutation: 6% vs 30%–50%
of eyes achieving a BCVA <0.1).1 6 8 20 21 Mitochondrial turn-
over is implicated in the pathogenesis of LHON, both mito-
chondrial biogenesis and mitophagy being increased in
fibroblasts of patients with LHON.23 24 The known age-related
decline in mitophagy, and hence presumably mitochondrial bio-
genesis, may underlie this difference from adult disease.25
In conclusion, childhood-onset LHON represents a distinct
phenotypical subgroup characterised by a more varied clinical
evolution and a more favourable visual prognosis compared
with classical adult LHON. Importantly, children do not always
develop acute or subacute visual symptoms and a high index of
suspicion is required in children presenting with unexplained
subnormal vision and optic disc pallor to avoid potentially long
diagnostic delays.
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